Maverick Capital’s Quest Diagnostics DGX Stock Holding History

Maverick Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,756	Closed	-$540K	–	215
2026 Q1	$540K	Sell	2,756 -21,139	-88%	-$4.11M	0.01%	218
2025 Q4	$4.15M	Buy	23,895 +5,717	+31%	+$1.04M	0.04%	97
2025 Q3	$3.46M	Buy	+18,178	New	+$3.23M	0.05%	116
2023 Q3	–	Sell	-8,046	Closed	-$1.13M	–	365
2023 Q2	$1.13M	Buy	8,046 +2,503	+45%	+$345K	0.02%	154
2023 Q1	$784K	Buy	+5,543	New	+$793K	0.02%	180
2021 Q2	–	Sell	-2,441	Closed	-$313K	–	714
2021 Q1	$313K	Buy	2,441 +1,813	+289%	+$223K	﹤0.01%	435
2020 Q4	$75K	Buy	+628	New	+$76.6K	﹤0.01%	602
2016 Q4	–	Sell	-37,510	Closed	-$3.17M	–	131
2016 Q3	$3.17M	Buy	+37,510	New	+$3.15M	0.04%	56

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Maverick Capital's DGX Position: Q2 2026 in Review

Maverick Capital sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 2,756 shares — an estimated $540K sold.

Maverick Capital first reported a position in DGX in Q3 2016 and held it in 8 quarters. The position peaked at $4.15M in Q4 2025. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Maverick Capital reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
Maverick Capital sold 2,756 Quest Diagnostics shares in Q2 2026, an estimated $540K.
Maverick Capital first reported a position in Quest Diagnostics in Q3 2016 and held it in 8 quarters.
Maverick Capital's Quest Diagnostics position peaked at $4.15M in Q4 2025.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.